Related Experiment Videos
Prolonged red cell survival following in vitro treatment with potassium cyanate. A study in patients undergoing
Insights
Potassium cyanate treatment improved red blood cell survival in patients undergoing heart surgery. This enhanced red cell survival indicates better tolerance to cardiopulmonary bypass trauma.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Biomedical Engineering
Background:
- Cardiopulmonary bypass (CPB) is a critical procedure in cardiac surgery.
- CPB can cause significant trauma to red blood cells, impacting their survival.
- Optimizing red blood cell (RBC) preservation during CPB is essential for patient outcomes.
Purpose of the Study:
- To prospectively evaluate the effect of potassium cyanate treatment on red blood cell survival in patients undergoing cardiac surgery.
- To compare RBC survival rates in patients undergoing single valve replacement (SVR) versus coronary artery bypass grafting (CABG).
- To assess the protective effect of cyanate treatment against RBC damage during CPB.
Main Methods:
- Prospective study involving 48 patients undergoing CPB for SVR or CABG.
- Red blood cells were labeled with Chromium-51 before surgery.
- RBCs were treated with potassium cyanate or invertose alone prior to CPB.
Main Results:
- Mean RBC survival was significantly longer in cyanate-treated groups (21.3 days for SVR, 23 days for CABG) compared to control groups (12.7 days for SVR, 12 days for CABG).
- Cyanate treatment led to significantly less isotope loss during CPB and the early postoperative period.
- This indicates improved RBC tolerance to the mechanical stress of CPB.
Conclusions:
- Potassium cyanate treatment enhances red blood cell survival following cardiopulmonary bypass.
- Cyanate offers a protective effect, improving RBC tolerance to CPB-induced trauma.
- This finding suggests a potential strategy to mitigate RBC damage during cardiac surgery.
Abstract:
Red cel survival was prospectively studied, using Chromium-51 isotope, in 48 patients undergoing cardiopulmonary bypass for single valve replacement (SVR, 24 patients) or coronary bypass graft procedures (CABG, 24 patients). The red cells were labelled on the day before the open heart surgery. Cells from randomly selected patients were treated for 30 min with potassium cyanate (0.5 mg/100 ml) in 5% invertose solution or with 5% invertose alone. The mean red cell survival in the SVR and the CABG group was 21.3 and 23 days, respectively, when the cells had been treated with cyanate, and 12.7 and 12 days when only invertose had been used. In the cyanate groups the loss of isotope during cardiopulmonary bypass and in the first three postoperative days was significantly less than in the control groups indicating improved tolerance to the traumatic effects of cardiopulmonary bypass.